Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.
The new report entitled Colorectal Cancer (Stage IV): Blockbuster Opportunity Awaits a Therapy That Would Improve Overall Survival over IFL/Bevacizumab finds that the 4.7 month increase in median overall survival achieved by IFL/bevacizumab over IFL alone in 2004 in the landmark AVF-2107 clinical trial remains unsurpassed by any emerging therapy evaluated in Phase III clinical trials conducted in recent years.
The report also finds that FOLFOX4 (5-fluorouracil, generics/leucovorin, generics/oxaliplatin [Sanofi-Aventis's Eloxatin/Eloxatine, Yakult Honsha's Elplat, generics]) plus bevacizumab will retain Decision Resources' proprietary clinical gold-standard status for first-line treatment of stage IV colorectal cancer through 2018. In 2009, FOLFOX4/bevacizumab earned gold-standard status owing primarily to the optimal combination of efficacy and acceptable safety and tolerability as compared to other current and emerging therapies. Based on available data and expert opinion, no other therapy in development is expected to displace FOLFOX4/bevacizumab as the clinical gold standard for first-line treatment of stage IV colorectal cancer. While some therapies in development for the indication hold promise, most have efficacy, safety and tolerability and/or delivery features that are inferior when compared to FOLFOX4/bevacizumab.
"Surveyed oncologists say that a therapy's effect on overall survival is the attribute that most influences their prescribing decisions in the treatment of stage IV colorectal cancer," said Decision Resources Analyst Natalia Reoutova. "Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over sales-leading FOLFOX4/bevacizumab on this attribute."
*Irinotecan (Pfizer's Camptosar, Yakult Honsha's Campto, Daiichi Sankyo's Topotecin, generics)
About the Report
Colorectal Cancer (Stage IV): Blockbuster Opportunity Awaits a Therapy That Would Improve Overall Survival over IFL/Bevacizumab is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Christopher Comfort 781-296-2597 email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort, Decision Resources, +1-781-296-2597,
Web Site: http://www.decisionresources.com/